Clinical trials: RANDOMIZED
Cardiovascular Disease, Pulmonary Arterial Hypertension
Effect of BIA 5 1058 on Cardiac Repolarization
The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)
- Conditions
- Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure
- Trial name
- NCT03489005
- Testing
- BIA 5-1058, Moxifloxacin 400 mg
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Gastroenteritis
Ondansetron Versus Metoclopramide in Treatment of Vomiting in Gastroenteritis
Is intravenous metoclopramid as effective as intravenous ondansetron in the treatment of persistent vomiting in patients with acute gastroenteritis.
- Trial name
- NCT01165866
- Testing
- Treatment 1. Metoclopramide, Treatment 2 Ondansetron
- Where
- Qatar
- Volunteers
- 170 people
- Sponsor
- Hamad Medical Corporation
Healthy
Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions
The objective of this study is to compare the rate and extent of absorption of ziprasidone 20 mg capsules versus Geodon 20 mg capsules under fasting conditions.
- Trial name
- NCT01581866
- Testing
- Ziprasidone Hydrochloride
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Type 1 Diabetes Mellitus
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of TI Inhalation Power in combination with a basal insulin versus insulin aspart in combination with a basal insulin
- Trial name
- NCT01445951
- Testing
- Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
- Where
- 90 sites in United States, Brazil and 2 more
- Volunteers
- 518 people
- Sponsor
- Mannkind Corporation
Healthy Male Volunteer
The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea
To assess the pharmacokinetic Interaction between CKD-501 and sulfonylurea (Glimepiride) in healthy male subjects.
- Trial name
- CKD-501 DDI (NCT01133431)
- Testing
- CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteers
Trial on Single/Multiple Ascending Doses for Safety, PK and PD for CBP-0276 in Healthy Subjects
A double-blind, randomized, placebo-controlled, single and multiple ascending dose study with food effect to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-0276.
- Trial name
- CBP276SADMAD (NCT07708831)
- Testing
- CBP-0276 Acetate
- Where
- 2 sites in Mexico
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Clarent Biopharma, Inc.
Spinal Muscular Atrophy, Neuromuscular Diseases
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
This trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of nusinersen and/or risdiplam and/or have a history of onasemnogene abeparvovec…
- Conditions
- Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
- Trial name
- RESILIENT (NCT05337553)
- Testing
- taldefgrobep alfa
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 269 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Bladder Cancer
A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
This is a randomized, multicenter, two-arm, double-blind, placebo-controlled study of Qapzola in participants with low- to intermediate-risk non-muscle invasive bladder cancer (NMIBC), assessed according to the 2016 American…
- Trial name
- NCT03224182
- Testing
- Qapzola
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Advanced Breast Cancer
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
- Trial name
- VERITAC-2 (NCT05654623)
- Testing
- ARV-471, Fulvestrant
- Where
- 312 sites in United States, Argentina and 29 more
- Volunteers
- 624 people
- Sponsor
- Pfizer
Gut Microbiota
Effects of Riboflavin on Faecalibacterium Prausnitzii and the Gut Microbiota
The purpose of this trial is to investigate comprehensively the effect of riboflavin supplementation on the abundance of F. prausnitzii and on other members of the gut microbiota in faeces of healthy volunteers.
- Trial name
- NCT02929459
- Testing
- Riboflavin Dose 1, Riboflavin Dose 2
- Where
- Netherlands
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Juvenile Idiopathic Arthritis
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to…
- Trial name
- NCT01230827
- Testing
- CNTO 148 (Golimumab), Methotrexate
- Where
- 35 sites in United States, Austria and 10 more
- Volunteers
- 173 people
- Sponsor
- Janssen Research & Development, LLC
Myelofibrosis, Anemia
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo.
- Trial name
- ELRISE MF (NCT07623161)
- Testing
- Elritercept
- Where
- 195 sites in United States, Argentina and 29 more
- Volunteers
- 324 people
- Sponsor
- Takeda
Irritable Bowel Syndrome With Diarrhea (IBS-D)
G-PUR® for Symptomatic Treatment in Irritable Bowel Syndrome With Diarrhea
A randomized, double-blind, placebo-controlled pilot study in patients with IBS-D according to Rome IV criteria evaluating the clinical efficacy and safety of oral administration of 2g G-PUR® tid compared to placebo in a cohort…
- Trial name
- NCT04138186
- Testing
- 2.0g G-PUR®, oral administration
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Glock Health, Science and Research GmbH
Healthy Subjects
A Study of SYHA1805 in Healthy Subjects
This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose of SYHA1805.
- Trial name
- NCT04977570
- Testing
- SYHA1805 tablets
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Atopic Disease (Including Allergic Conjunctivitis)
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).
- Trial name
- NCT02132169
- Testing
- Drug: AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- Aciex Therapeutics, Inc.
Breast Cancer
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
This study is a randomized controlled, open-label, multicenter phase III clinical study evaluating the efficacy and safety of chemotherapy selected by investigator JSKN003 s in subjects with recurrent or metastatic breast cancer…
- Trial name
- NCT06079983
- Testing
- JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection
- Where
- 87 sites in China
- Volunteers
- 400 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
This study is testing CG2001, a new medicine that is applied as a light foam to the scalp and is being developed to treat male-pattern hair loss (androgenetic alopecia). The main goals are to find out: 1.
- Trial name
- NCT07038941
- Testing
- CG2001
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Beijing Dayspring Pharmaceutical Technology Co., Ltd
Intermittent Urethral Catheterization
Evaluation of a New Catheter Coating Process for Urinary Catheters Used for Intermittent Catheterization.
This is a prospective, double-blinded, randomized, multi-centre, cross-over study. All subjects will use both the study device (test catheter) and the comparator (control catheter) for one week each.
- Trial name
- NCT03684941
- Testing
- Treatment Period One, Treatment Period Two
- Where
- 8 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Dentsply International
Diabetic Foot, Diabetic Foot Ulcer
SkinTE™ in the Treatment of Diabetic Foot Wounds
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on a commercially available human autologous homologous skin construct with SOC dressing compared to SOC dressings…
- Conditions
- Diabetic Foot, Diabetic Foot Ulcer, Ulcer Foot
- Trial name
- NCT03881254
- Testing
- Human Autologous Homologous Skin Construct, Additional Outer Dressing Applicaiton, Offloading
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- PolarityTE
Esophageal Squamous Cell Carcinoma
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
The study aimed to evaluate the efficacy and safety of sitravatinib in combination with tislelizumab as a second- or third-line treatment for participants with locally advanced, unresectable, or metastatic esophageal squamous…
- Trial name
- NCT05461794
- Testing
- Sitravatinib, Tislelizumab, Docetaxel
- Where
- 31 sites in China
- Volunteers
- 96 people
- Sponsor
- BeiGene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.